FY2025 · ended Dec 31, 2025 · Revenue $44.64M, -6.1% YoY · Filed Mar 27, 2026
Fennec Pharmaceuticals Inc. (FENC) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $44.6 million and a net loss of $9.7 million.
Revenue (TTM)
$59.22M
+77.8% vs year-ago TTM
Net income (TTM)
$-3.25M
+73.0% vs year-ago TTM
Operating cash flow (TTM)
$-2.04M
+82.5% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.10
+79.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
34.48M
+24.9% vs prior year
Net cash
$7.29M
FY 2024
Operating margin
-1.9%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FENC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Research Triangle Park, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1211583
- Former names
- ADHEREX TECHNOLOGIES INC (until Aug 14, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $21.3M | — | — |
| Operating income | -$6.3M | $2.6M | -$12.8M | -$22.6M | -$17.2M |
| Net income | -$9.7M | -$436,000 | -$16.0M | -$23.7M | -$17.3M |
| Diluted EPS | -$0.34 | -$0.02 | -$0.60 | -$0.90 | -$0.67 |
| Operating cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M | -$14.2M |
| Total assets | $70.6M | $44.9M | $26.9M | $26.9M | $22.4M |
| Total liabilities | $35.1M | $50.8M | $38.5M | $29.5M | $6.6M |
| Stockholders' equity | $35.5M | -$5.9M | -$11.6M | -$2.6M | $15.8M |
| Cash and investments | $36.8M | $26.6M | $13.3M | $23.8M | $21.1M |
| Total debt | — | $19.3M | $31.0M | $24.9M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 17, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Other events
|
May 22, 2026 | May 21, 2026 |
| 8-K |
Current report
Officer or director change
|
May 18, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 853 Fennec Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.